Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer

Journal of Clinical Oncology

Volumn 14, Issue 8, 1996, Pages 2234-2241

  Gause, B L ^a   Sznol, M ^a   Kopp, W C ^a   Janik, J E ^a   Smith, II ^a   Steis, R G ^a   Urba, W J ^a   Sharfman, W ^a   Fenton, R G ^a   Creekmore, S P ^a   Holmlund, J ^a   Conlon, K C ^a   VanderMolen, L A ^a   Longo, D L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; NEOPTERIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; HYPOTENSION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MYOSITIS; OUTPATIENT CARE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 9444280130     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.8.2234     Document Type: Article

References (27)

1. Rosenberg SA: Karnofsky memorial lecture: The immunotherapy and gene therapy of cancer. J Clin Oncol 10:180-199, 1992
2. Atkins MB, Sparano J, Fisher RI, et al: Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alpha-2b in advanced renal cell carcinoma. J Clin Oncol 11:661-670, 1993
3. Parkinson DR, Abrams JS, Wiernik PH, et al: Interleukin-2 therapy in patients with metastatic malignant melanoma: A phase II study. J Clin Oncol 8:1650-1656, 1990
4. Siegel JP, Puri RK: Interleukin-2 toxicity. J Clin Oncol 9:694-704, 1991
5. Guadagni F, Schlom J, Johnston WW, et al: Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells. J Natl Cancer Inst 81:502-511, 1989
6. Weber JS, Rosenberg SA: Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro. Cancer Res 48:5818-5824, 1988
7. Muss HB: Renal cell carcinoma, in De Vita VT, Helman S, Rosenberg SA (eds): Biologic Therapy of Cancer. Philadelphia, PA, Lippincott, 1991, pp 298-311
8. Creagan ET, Ahmann DL, Frytak S, et al: Three consecutive phase II studies of recombinant Interfere n-alpha-2 A in advanced malignant melanoma. Cancer 59:638-646, 1987
9. Cameron RB, McIntosh JK, Rosenberg SA: Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid α-interferon in the treatment of established murine hepatic metastases. Cancer Res 48:5810-5817, 1988
10. Iigo M, Sakurai M, Tamura T, et al: In vivo antitumor activity of multiple injections of recombinant interleukin-2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumor. Cancer Res 48:260-264, 1988
11. Rosenberg SA, Lotze MT, Yang JC, et al: Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 7:1863-1874, 1989
12. Rosenberg SA: Adoptive Immunotherapy of cancer using lymphokine activated killer cells and recombinant IL-2, in DeVita VT, Hellman S, Rosenberg SA (eds): Important Advances in Oncology. Philadelphia, PA, Lippincott, 1986, pp 55-91
13. Creagan ET, Schaid DJ, Ahman DL, et al: Recombinant interferons in the management of advanced malignant melanoma. Am J Clin Oncol 11:652-659, 1988
14. Maluish AE, Urba WJ, Longo DL, et al: The determination of an immunologically active dose of interferon-gamma in patients with melanoma. J Clin Oncol 6:434-444, 1988
15. Pross H, Baines MT, Rubin P, et al: Spontaneous human lymphocyte mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J Clin Immunol 1:51-63, 1981
16. Sznol M, Thurn A, Aronson FR: Interleukin-2 in combination with other biologic agents, in Atkins MB, Mier JW (eds): Therapeutic Applications of IL-2. New York, NY, Marcel Dekker, 1993, pp 233-275
17. Atzpodien J, Korfer A, Menzel T, et al: Home therapy using recombinant human IL-2 and IFN-α2B in patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 10:177, 1991 (abstr)
18. Kruit WHJ, Bolhuis RLH, Goey SH, et al: Interleukin-2 induced thyroid dysfunction is correlated with treatment duration but not with tumor response. J Clin Oncol 11:921-924, 1993
19. Schwarzentruber DJ, White DE, Zweig MH, et al: Thyroid dysfunction associated with immunotherapy for patients with cancer. Cancer 68:2384-2390, 1991
20. Sleijfer DTh, Janssen RAJ, Buter J et al: Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol 10:1119-1123, 1993
21. Figlin RA, Belldegrun A, Moldawer N, et al: Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2a: An active outpatient regimen in metastatic renal cell carcinoma. J Clin Oncol 10:414-421, 1992
22. Demchak P, Atkins M, Sell K, et al: Phase II study of interleukin-2 and interferon alpha-2a outpatient therapy for metastatic renal cancer. Proc Am Soc Clin Oncol 10:175, 1991 (abstr)
23. Dutcher JP, Fisher RI, Weiss GR, et al: An outpatient (opt) regimen of subcutaneous (sc) interleukin-2 (IL-2) plus alpha-interferon (IFN) in metastatic renal cell cancer (RCC). Proc Am Soc Clin Oncol 12:248, 1993 (abstr)
24. Minasian LM, Motzer RJ, Mazumdar M, et al: Interferon Alfa-2a in Advanced Renal Cell Carcinoma: Treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 11:1368-1375, 1993
25. Janik J, Kopp WC, Smith JW II, et al: Dose-related immunologic effects of levamisole in patients with cancer. J Clin Oncol 11:125-135, 1993
26. Kopp WC, Smith JW II, Ewel CH,et al: Immunomodulatory effects of interferon-γ in patients with metastatic malignant melanoma. J Immunother 13:181-190, 1993
27. Figlin RA, Pierce WC, Belldegrun A: Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma. Semin Oncol 20:11-15, 1993